Evolution of endocrine therapy for advanced prostate cancer: Breakthroughs and resistance mechanisms from traditional antiandrogens to novel AR pathway inhibitors
Ziqiang Liu, Jianhua Xiao, Ziqiang Dong. Evolution of endocrine therapy for advanced prostate cancer: Breakthroughs and resistance mechanisms from traditional antiandrogens to novel AR pathway inhibitors. // Letters in Drug Design & Discovery. – 2026. – DOI: 10.1016/j.lddd.2026.100637. – URL: https://doi.org/10.1016/j.lddd.2026.100637
Ziqiang Liu, Jianhua Xiao, & Ziqiang Dong (2026). Evolution of endocrine therapy for advanced prostate cancer: Breakthroughs and resistance mechanisms from traditional antiandrogens to novel AR pathway inhibitors. Letters in Drug Design & Discovery. https://doi.org/10.1016/j.lddd.2026.100637
Ziqiang Liu, et al. “Evolution of endocrine therapy for advanced prostate cancer: Breakthroughs and resistance mechanisms from traditional antiandrogens to novel AR pathway inhibitors.” Letters in Drug Design & Discovery, 2026. doi:10.1016/j.lddd.2026.100637.
@article{Liu2026,
title = {Evolution of endocrine therapy for advanced prostate cancer: Breakthroughs and resistance mechanisms from traditional antiandrogens to novel AR pathway inhibitors},
author = {Liu, Ziqiang and Xiao, Jianhua and Dong, Ziqiang},
journal = {Letters in Drug Design \& Discovery},
year = {2026},
doi = {10.1016/j.lddd.2026.100637},
url = {https://doi.org/10.1016/j.lddd.2026.100637}
}